Pharmaceuticals & Therapeutics

Beyond the hype, Eisai's latest data on at-home Alzheimer's treatment and a new anti-tau drug signals a seismic shift in patient care and market strategy.

Larimar Therapeutics is rewriting the rare disease playbook. Its BLA filing for nomlabofusp leverages a novel FDA-aligned endpoint, creating a de-risked path to market.

WideTrial's innovative program hit a major milestone, providing 200 ALS patients with an investigational drug and creating a new model for compassionate use.

Viridian's Lumvoa gains FDA approval for Thyroid Eye Disease, challenging a blockbuster drug and validating DRI Healthcare's unique royalty investment model.

In a major show of biotech investor confidence, Talawar Therapeutics is going public via a SPAC merger, securing $285M to advance its novel bispecific antibody.

A German biotech just completed a key trial for a cell therapy that could teach the body to accept a new kidney, freeing patients from a lifetime of harsh drugs.

For over a million Europeans with Parkinson's, a new drug promises longer periods of symptom control. But the path from regulatory approval to patient is complex.

Positive interim data for a world-first CBD insomnia trial de-risks development, promising a safer alternative to current drugs and igniting global interest.

A rare disease drug's EU approval is revoked over 'misleading' data, impacting patients and signaling a new era of strict regulatory scrutiny for pharma giants.

Swiss drugmaker Idorsia's new financing buys precious time, fueling its blockbuster hopeful QUVIVIQ and securing its ambitious R&D pipeline.

New data on a once-weekly drug and a novel combination therapy signal a major shift in treating achondroplasia, moving the focus from height to quality of life.

As MAPS announces its 2027 summit, the psychedelic field grapples with a critical question: can its visionary promise survive the harsh pressures of reality?

Following promising clinical data, biotech firm Immunis unveils a new brand identity, signaling a strategic shift toward multi-pathway biologics for healthy aging.

ZOIA and Meta Healthcare's alliance brings a ready-to-use liquid nutrition to the US, promising to ease the daily burden for those with a rare metabolic disorder.

Positive Phase 3b data for Otsuka's centanafadine could revolutionize treatment for millions battling both ADHD and anxiety with a single, first-in-class drug.

A landmark publication in The Lancet unveils AC01, a novel oral drug that safely improves heart function, offering a beacon of hope for millions with heart failure.

A landmark survey reveals a stunning bipartisan mandate on reproductive health, showing a vast majority of Republican voters support protecting access to EC.

With late-stage veterans on board, MRM Health isn't just advancing a drug; it's building the strategic architecture for microbiome's leap from lab to market.

By fast-tracking its novel oral drug for atopic dermatitis, Kymera isn't just advancing a treatment—it's validating a new class of medicine.